Followers | 0 |
Posts | 14 |
Boards Moderated | 0 |
Alias Born | 09/18/2018 |
Tuesday, November 27, 2018 5:57:19 PM
CHICAGO, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. ("the Company") (OTCQB:COSM), an international pharmaceutical company, announced that it has added a new member to its advisory board. Mr. Anastasios Tzikas is the president of several organizations including: Thessaloniki International Fair HELEXPO SA, Federation of Hellenic Information Technology & Communications (SEPE), and Technopolis Thessaloniki ICT Business Park. He is also one of the founders & former CEO of Singular Northern Greece SA, one of the largest software vendor and integrated IT solutions group in Greece and Balkans area.
"Anastasios Tzikas brings a wealth of expertise and experience to our company," said Grigorios Siokas, Chief Executive Officer of Cosmos Holdings. "His tenure as former CEO of a listed multinational company and as president of well-recognized organizations makes him a great addition to our advisory board. We are excited to welcome him to the Cosmos team and look forward to his insight and contribution to our strategy for healthcare IT solutions.
New advisory board member Anastasios Tzikas stated: "Cosmos Holding Inc. is a vibrant international company, with an emphasis on innovation and extroversion. It is therefore a major challenge for me to personally assist this company in integrating new technologies into its core business and developing synergies in the sectors of e-health and biotech."
About Cosmos Holdings, Inc.
Cosmos Holdings Inc. is an international pharmaceutical company focused on identifying, acquiring, developing, and commercializing medicines to improve patients' lives and outcomes. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece & in Harlow, UK. More information is available at www.cosmosholdingsinc.com.
FORWARD LOOKING STATEMENTS
Except for historical information, this news release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve unknown risks, and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Important factors that might cause such differences are discussed in the Company's filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results could differ materially from those anticipated in these forward-looking statements, if new information becomes available in the future.
Recent COSM News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/07/2024 09:31:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 03:21:53 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/09/2024 05:15:09 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/29/2024 10:15:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:19:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/29/2023 10:00:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/29/2023 11:02:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 09:05:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 09:05:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 02:30:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 02:16:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/12/2023 01:43:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2023 08:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:05:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 08:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/14/2023 09:17:17 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM